Efficacy and Safety of Low‐Frequency Daratumumab Regimen in Systemic Light‐Chain Amyloidosis

ABSTRACT In recent years, daratumumab has been increasingly applied in the treatment of systemic light‐chain (AL) amyloidosis, significantly improving the prognosis of patients. Currently, the internationally recognized daratumumab treatment regimen comes from the ANDROMEDA trial. Given the low tumo...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Jintao Lin, Hui Yan, Xinyi Meng, Jingsong He, Jinuo Wang, Xiaoyan Han, Jian Shen, Qiu Fang, Li Huang, Gaofeng Zheng, Wenjun Wu, Yi Zhao, Yi Li, Li Yang, Xing Guo, Jing Chen, Haimeng Yan, Zhen Cai, Donghua He
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Wiley 2026-07-01
Serie:	Cancer Medicine
Soggetti:	AL amyloidosis CD38 daratumumab Low‐frequency therapy plasma‐cell
Accesso online:	https://doi.org/10.1002/cam4.72103
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!